These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 30878825)
1. Synthesis of novel 7-azaindole derivatives containing pyridin-3-ylmethyl dithiocarbamate moiety as potent PKM2 activators and PKM2 nucleus translocation inhibitors. Liu B; Yuan X; Xu B; Zhang H; Li R; Wang X; Ge Z; Li R Eur J Med Chem; 2019 May; 170():1-15. PubMed ID: 30878825 [TBL] [Abstract][Full Text] [Related]
2. Synthesis of novel sulfonamide derivatives containing pyridin-3-ylmethyl 4-(benzoyl)piperazine-1-carbodithioate moiety as potent PKM2 activators. Li R; Ning X; He J; Lin Z; Su Y; Li R; Yin Y Bioorg Chem; 2021 Mar; 108():104653. PubMed ID: 33517002 [TBL] [Abstract][Full Text] [Related]
3. Discovery and structure-activity relationship of novel 4-hydroxy-thiazolidine-2-thione derivatives as tumor cell specific pyruvate kinase M2 activators. Li R; Ning X; Zhou S; Lin Z; Wu X; Chen H; Bai X; Wang X; Ge Z; Li R; Yin Y Eur J Med Chem; 2018 Jan; 143():48-65. PubMed ID: 29172082 [TBL] [Abstract][Full Text] [Related]
4. Activators of PKM2 in cancer metabolism. Warner SL; Carpenter KJ; Bearss DJ Future Med Chem; 2014 Jun; 6(10):1167-78. PubMed ID: 25078136 [TBL] [Abstract][Full Text] [Related]
5. New pyridin-3-ylmethyl carbamodithioic esters activate pyruvate kinase M2 and potential anticancer lead compounds. Zhang Y; Liu B; Wu X; Li R; Ning X; Liu Y; Liu Z; Ge Z; Li R; Yin Y Bioorg Med Chem; 2015 Aug; 23(15):4815-4823. PubMed ID: 26081759 [TBL] [Abstract][Full Text] [Related]
6. 1-(sulfonyl)-5-(arylsulfonyl)indoline as activators of the tumor cell specific M2 isoform of pyruvate kinase. Yacovan A; Ozeri R; Kehat T; Mirilashvili S; Sherman D; Aizikovich A; Shitrit A; Ben-Zeev E; Schutz N; Bohana-Kashtan O; Konson A; Behar V; Becker OM Bioorg Med Chem Lett; 2012 Oct; 22(20):6460-8. PubMed ID: 22963766 [TBL] [Abstract][Full Text] [Related]
7. Discovery of 3-(trifluoromethyl)-1H-pyrazole-5-carboxamide activators of the M2 isoform of pyruvate kinase (PKM2). Xu Y; Liu XH; Saunders M; Pearce S; Foulks JM; Parnell KM; Clifford A; Nix RN; Bullough J; Hendrickson TF; Wright K; McCullar MV; Kanner SB; Ho KK Bioorg Med Chem Lett; 2014 Jan; 24(2):515-9. PubMed ID: 24374270 [TBL] [Abstract][Full Text] [Related]
8. Pyruvate kinase activators as a therapy target: a patent review 2011-2017. Adem S; Comakli V; Uzun N Expert Opin Ther Pat; 2018 Jan; 28(1):61-68. PubMed ID: 28994333 [TBL] [Abstract][Full Text] [Related]
9. Targeting pyruvate kinase muscle isoform 2 (PKM2) in cancer: What do we know so far? Chhipa AS; Patel S Life Sci; 2021 Sep; 280():119694. PubMed ID: 34102192 [TBL] [Abstract][Full Text] [Related]
10. Discovery of 2-((1H-benzo[d]imidazol-1-yl)methyl)-4H-pyrido[1,2-a]pyrimidin-4-ones as novel PKM2 activators. Guo C; Linton A; Jalaie M; Kephart S; Ornelas M; Pairish M; Greasley S; Richardson P; Maegley K; Hickey M; Li J; Wu X; Ji X; Xie Z Bioorg Med Chem Lett; 2013 Jun; 23(11):3358-63. PubMed ID: 23622982 [TBL] [Abstract][Full Text] [Related]
11. Combining structure-based pharmacophore modeling, virtual screening, and in silico ADMET analysis to discover novel tetrahydro-quinoline based pyruvate kinase isozyme M2 activators with antitumor activity. Chen C; Wang T; Wu F; Huang W; He G; Ouyang L; Xiang M; Peng C; Jiang Q Drug Des Devel Ther; 2014; 8():1195-210. PubMed ID: 25214764 [TBL] [Abstract][Full Text] [Related]
12. Pharmacologic activation of PKM2 slows lung tumor xenograft growth. Parnell KM; Foulks JM; Nix RN; Clifford A; Bullough J; Luo B; Senina A; Vollmer D; Liu J; McCarthy V; Xu Y; Saunders M; Liu XH; Pearce S; Wright K; O'Reilly M; McCullar MV; Ho KK; Kanner SB Mol Cancer Ther; 2013 Aug; 12(8):1453-60. PubMed ID: 23720766 [TBL] [Abstract][Full Text] [Related]
13. Discovery of boronic acid-based potent activators of tumor pyruvate kinase M2 and development of gastroretentive nanoformulation for oral dosing. Patle R; Shinde S; Patel S; Maheshwari R; Jariyal H; Srivastava A; Chauhan N; Globisch C; Jain A; Tekade RK; Shard A Bioorg Med Chem Lett; 2021 Jun; 42():128062. PubMed ID: 33901643 [TBL] [Abstract][Full Text] [Related]
14. Natural Product Micheliolide (MCL) Irreversibly Activates Pyruvate Kinase M2 and Suppresses Leukemia. Li J; Li S; Guo J; Li Q; Long J; Ma C; Ding Y; Yan C; Li L; Wu Z; Zhu H; Li KK; Wen L; Zhang Q; Xue Q; Zhao C; Liu N; Ivanov I; Luo M; Xi R; Long H; Wang PG; Chen Y J Med Chem; 2018 May; 61(9):4155-4164. PubMed ID: 29641204 [TBL] [Abstract][Full Text] [Related]
15. NAMPT regulates PKM2 nuclear location through 14-3-3ζ: Conferring resistance to tamoxifen in breast cancer. Ge X; Zhao Y; Dong L; Seng J; Zhang X; Dou D J Cell Physiol; 2019 Dec; 234(12):23409-23420. PubMed ID: 31141164 [TBL] [Abstract][Full Text] [Related]
16. PKM2 Thr454 phosphorylation increases its nuclear translocation and promotes xenograft tumor growth in A549 human lung cancer cells. Yu Z; Huang L; Qiao P; Jiang A; Wang L; Yang T; Tang S; Zhang W; Ren C Biochem Biophys Res Commun; 2016 May; 473(4):953-958. PubMed ID: 27045080 [TBL] [Abstract][Full Text] [Related]
17. Benserazide is a novel inhibitor targeting PKM2 for melanoma treatment. Zhou Y; Huang Z; Su J; Li J; Zhao S; Wu L; Zhang J; He Y; Zhang G; Tao J; Zhou J; Chen X; Peng C Int J Cancer; 2020 Jul; 147(1):139-151. PubMed ID: 31652354 [TBL] [Abstract][Full Text] [Related]
18. A new SIRT1 inhibitor, MHY2245, induces autophagy and inhibits energy metabolism via PKM2/mTOR pathway in human ovarian cancer cells. Tae IH; Son JY; Lee SH; Ahn MY; Yoon K; Yoon S; Moon HR; Kim HS Int J Biol Sci; 2020; 16(11):1901-1916. PubMed ID: 32398958 [TBL] [Abstract][Full Text] [Related]
19. Nuclear translocation of PKM2/AMPK complex sustains cancer stem cell populations under glucose restriction stress. Yang YC; Chien MH; Liu HY; Chang YC; Chen CK; Lee WJ; Kuo TC; Hsiao M; Hua KT; Cheng TY Cancer Lett; 2018 May; 421():28-40. PubMed ID: 29408265 [TBL] [Abstract][Full Text] [Related]
20. PKM2 Subcellular Localization Is Involved in Oxaliplatin Resistance Acquisition in HT29 Human Colorectal Cancer Cell Lines. Ginés A; Bystrup S; Ruiz de Porras V; Guardia C; Musulén E; Martínez-Cardús A; Manzano JL; Layos L; Abad A; Martínez-Balibrea E PLoS One; 2015; 10(5):e0123830. PubMed ID: 25955657 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]